Cardioloxía
Servicio
Brigham and Women's Hospital
Boston, Estados UnidosPublicacións en colaboración con investigadores/as de Brigham and Women's Hospital (33)
2024
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA
Circulation, Vol. 150, Núm. 2, pp. 165-167
2023
-
Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology
European Journal of Heart Failure, Vol. 25, Núm. 4, pp. 457-468
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45
-
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
JACC: Heart Failure, Vol. 11, Núm. 12, pp. 1729-1738
2022
-
Assessment of Omecamtiv Mecarbil for the Treatment of Patients with Severe Heart Failure: A Post Hoc Analysis of Data from the GALACTIC-HF Randomized Clinical Trial
JAMA Cardiology, Vol. 7, Núm. 1, pp. 26-34
-
Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial
European heart journal, Vol. 43, Núm. 2, pp. 148-149
-
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198
-
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry
European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1305-1315
-
Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial
Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661
-
Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
Journal of the American College of Cardiology, Vol. 79, Núm. 20, pp. 2001-2017
2021
-
Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry
Circulation: Cardiovascular Interventions, Vol. 14, Núm. 5, pp. E010195
2020
-
Initial invasive or conservative strategy for stable coronary disease
New England Journal of Medicine, Vol. 382, Núm. 15, pp. 1395-1407
-
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 396, Núm. 10253, pp. 759-769
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171
2019
-
Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry
European Journal of Heart Failure, Vol. 21, Núm. 9, pp. 1129-1141
-
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107